Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract

BodeVet, Inc., a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 2-year contract valued at $1.7 million to conduct a clinical trial in canine polytrauma patients at veterinary critical care hospitals. The study is designed to evaluate the administration of two lyophilized blood products, StablePlate RX® Canine (lyophilized canine platelets) and StablePlas™ Canine (lyophilized canine plasma) and their effects on hemodynamic stabilization following trauma, and to determine survival benefit when compared to current veterinary standard of care for trauma resuscitation.

Read More on the BodeVet Website!

Full Article available here!